Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expanded access
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Omeros’s 8K filing here. About Omeros (Get Free Report) Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, […]
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Omeros’s 8K filing here. About Omeros (Get Free Report) Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, […]
